1. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases. (November 2022) Authors: Dutriaux, Caroline; Robert, Caroline; Grob, Jean-Jacques; Mortier, Laurent; Dereure, Olivier; Lebbe, Céleste; Mansard, Sandrine; Grange, Florent; Neidhardt, Eve-Marie; Lesimple, Thierry; Machet, Laurent; Bedane, Christophe; Maillard, Hervé; Dalac-Rat, Sophie; Nardin, Charlée; Szenik, Alexandra; D... Journal: European journal of cancer Issue: Volume 175(2022) Page Start: 254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib. (September 2021) Authors: Saiag, Philippe; Robert, Caroline; Grob, Jean-Jacques; Mortier, Laurent; Dereure, Olivier; Lebbe, Céleste; Mansard, Sandrine; Grange, Florent; Neidhardt, Eve-Marie; Lesimple, Thierry; Machet, Laurent; Bedane, Christophe; Maillard, Hervé; Dalac-Rat, Sophie; Nardin, Charlée; Szenik, Alexandra; Dend... Journal: European journal of cancer Issue: Volume 154(2021) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗